{"id":828314,"date":"2025-03-20T16:35:23","date_gmt":"2025-03-20T20:35:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/"},"modified":"2025-03-20T16:35:23","modified_gmt":"2025-03-20T20:35:23","slug":"emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/","title":{"rendered":"Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08"},"content":{"rendered":"
\n

GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee\u00a0under its 2023 Inducement Plan (the “Inducement Plan”).<\/p>\n

The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the \u201cEquity Award\u201d) as of March 15, 2025 in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The Equity Award will be fully vested on March 15, 2026, subject to the employee\u2019s continuous service through the vesting date.<\/p>\n

\n About Emergent BioSolutions<\/strong>\n <\/p>\n

At Emergent, our mission is to protect and save lives. For over 25 years, we\u2019ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare for today\u2019s health challenges and tomorrow\u2019s threats, visit our website<\/a> and follow us on LinkedIn<\/a>, X<\/a>, Instagram<\/a>, Apple Podcasts<\/a> and Spotify<\/a>.<\/p>\n

\n Investor Contact:<\/strong>
\n
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee\u00a0under its 2023 Inducement Plan (the “Inducement Plan”). The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the \u201cEquity Award\u201d) as of March 15, 2025 in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The Equity Award will be fully vested on March 15, 2026, subject to the employee\u2019s continuous service through the vesting date. About Emergent BioSolutions At … <\/p>\n

Continue reading “Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-828314","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEmergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee\u00a0under its 2023 Inducement Plan (the “Inducement Plan”). The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the \u201cEquity Award\u201d) as of March 15, 2025 in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The Equity Award will be fully vested on March 15, 2026, subject to the employee\u2019s continuous service through the vesting date. About Emergent BioSolutions At … Continue reading "Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-20T20:35:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODMzMSM2ODE2OTUyIzIwMTA4NjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08\",\"datePublished\":\"2025-03-20T20:35:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\\\/\"},\"wordCount\":219,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5ODMzMSM2ODE2OTUyIzIwMTA4NjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\\\/\",\"name\":\"Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5ODMzMSM2ODE2OTUyIzIwMTA4NjY=\",\"datePublished\":\"2025-03-20T20:35:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5ODMzMSM2ODE2OTUyIzIwMTA4NjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5ODMzMSM2ODE2OTUyIzIwMTA4NjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/","og_locale":"en_US","og_type":"article","og_title":"Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - Market Newsdesk","og_description":"GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee\u00a0under its 2023 Inducement Plan (the “Inducement Plan”). The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the \u201cEquity Award\u201d) as of March 15, 2025 in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The Equity Award will be fully vested on March 15, 2026, subject to the employee\u2019s continuous service through the vesting date. About Emergent BioSolutions At … Continue reading \"Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-20T20:35:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODMzMSM2ODE2OTUyIzIwMTA4NjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08","datePublished":"2025-03-20T20:35:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/"},"wordCount":219,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODMzMSM2ODE2OTUyIzIwMTA4NjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/","name":"Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODMzMSM2ODE2OTUyIzIwMTA4NjY=","datePublished":"2025-03-20T20:35:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODMzMSM2ODE2OTUyIzIwMTA4NjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODMzMSM2ODE2OTUyIzIwMTA4NjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=828314"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828314\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=828314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=828314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=828314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}